Seattle Genetics’stocks fall after announcement of clinical hold on several Phase 1 trials of Vadastuximab Talirine in acute myeloid leukemia
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response.
In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac…
No abstract available
Cytarabine (ara-C) is a well-established agent widely used for treating AML. Conventionally, it is combined with anthracyclines for treating newly diagnosed Acute Myeloid Leukaemia (AML). At higher doses it is combined with the purine analogue fludarabine plus idarubicin and G-CSF (FLAG-Ida) for the treatment of relapsed or refractory AML. Fludarabine is known to potentiate intracellular accumulation of the active cytotoxic metabolite ara-CTP from ara-C via inhibition of ribonucleotide reductase and the normal formation of endogenous dCTP , and removal of the inhibition of deoxycytidine kinase (dCK) by dCTP [2,3].
Condition: Acute Myeloid Leukemia (AML) Interventions: Drug: Venetoclax; Drug: Gilteritinib Sponsors: AbbVie; Astellas Pharma Inc; Genentech, Inc. Not yet recruiting
Conclusion: Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.Cell Physiol Biochem 2018;48:2061 –2073
Despite recent advances in the management of subpopulations of AML, overall outcomes remain unsatisfactory. Encouraging results were seen with alvocidib (formerly known as flavopiridol), a CDK9 inhibitor with pan-cyclin-dependent kinase (CDK) activity, followed by cytarabine and mitoxantrone (FLAM) in serial phase I-II studies in newly diagnosed AML patients [1 –7]. Therefore, we conducted a randomized phase II clinical trial comparing FLAM to cytarabine and daunorubicin (7 + 3) in newly diagnosed AML patients 18-70 years of age with non-favorable risk cytogenetics .
Acute panmyelosis with myelofibrosis (APMF) is a rare subtype of acute myeloid leukemia (AML) in the World Health Organization classification . APMF is characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly [2 –5]. A standard treatment has not been established for APMF. Treatment modalities for APMF have considerable heterogeneity, including chemotherapies such as danazol, lenalidomide, and zoledronate [2,3,6,7]. However, such treatments have limited efficacy and the vast majority of patients will die f rom progressive disease, such as bone marrow failure and development of overt AML.
Conditions: FLT3-ITD Mutation; AML Intervention: Drug: Sorafenib Sponsor: The University of Hong Kong Recruiting
ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.
Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report of Berlin-Frankfurt-Münster study group.
Haematologica. 2018 Aug 09;:
Authors: Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M
Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia have poor survival. We evaluated Gemtuzumab Ozogamicin (CD33-targeted drug) used on compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia-Berlin-F…